• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统多学科方法对胃肠胰神经内分泌肿瘤患者管理的初始影响。

Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.

机构信息

Department of Endocrinology & Diabetes Mellitus, St Vincent's University Hospital-University College Dublin, 4 Elm Park, Dublin 4, Ireland,

出版信息

Endocrine. 2013 Oct;44(2):504-9. doi: 10.1007/s12020-013-9910-5. Epub 2013 Mar 8.

DOI:10.1007/s12020-013-9910-5
PMID:23471696
Abstract

According to the international guidelines, a multidisciplinary approach is currently advised for the optimal care of patients with a gastroenteropancreatic neuroendocrine tumor (GEP NET). In our institution (tertiary care center), a systematic multidisciplinary approach was established in May 2007. In this study, we have aimed to assess the initial impact of establishing a systematic multidisciplinary approach to the management of GEP NET patients. We have collected and compared the biochemical, imaging, and pathological data and the therapeutic strategies in GEP NET patients diagnosed, treated, or followed-up from January 1993 to April 2007 versus GEP NET patients attending our institution after the multidisciplinary approach starting, from May 2007 to October 2008. Data of 91 patients before and 42 patients after the establishment of the multidisciplinary approach (total: 133 consecutive GEP NET patients) have been finally collected and analyzed. Before the establishment of the multidisciplinary approach, a lack of consistency in the biochemical, imaging, and pathological findings before treatment initiation as well as during follow-up of GEP NET patients was identified. These inconsistencies have been reduced by the systematic multidisciplinary approach. In addition, the therapeutic management of GEP NET patients has been altered by the multidisciplinary approach and became more consistent with recommended guidelines. We think that a systematic multidisciplinary approach significantly impacts on GEP NET patient care and should be established in all centers dealing with these tumors.

摘要

根据国际指南,目前建议采用多学科方法为胃胰肠神经内分泌肿瘤(GEP NET)患者提供最佳治疗。在我们的机构(三级保健中心),于 2007 年 5 月建立了系统的多学科方法。在这项研究中,我们旨在评估建立系统的多学科方法来管理 GEP NET 患者的初始影响。我们收集和比较了 1993 年 1 月至 2007 年 4 月诊断、治疗或随访的 GEP NET 患者的生化、影像和病理数据以及治疗策略,与 2007 年 5 月多学科方法开始后至 2008 年 10 月在我们机构就诊的 GEP NET 患者进行了比较。最终收集和分析了 91 例多学科方法建立前和 42 例建立后(共 133 例连续 GEP NET 患者)的数据。在多学科方法建立之前,发现 GEP NET 患者在开始治疗前以及在随访期间的生化、影像和病理发现缺乏一致性。这些不一致性通过系统的多学科方法得到了减少。此外,多学科方法改变了 GEP NET 患者的治疗管理,使其更符合推荐的指南。我们认为,系统的多学科方法显著影响 GEP NET 患者的治疗,应在所有处理这些肿瘤的中心建立。

相似文献

1
Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.系统多学科方法对胃肠胰神经内分泌肿瘤患者管理的初始影响。
Endocrine. 2013 Oct;44(2):504-9. doi: 10.1007/s12020-013-9910-5. Epub 2013 Mar 8.
2
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.胃肠胰神经内分泌肿瘤:ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2020 Jul;31(7):844-860. doi: 10.1016/j.annonc.2020.03.304. Epub 2020 Apr 6.
3
Gastroenteropancreatic Neuroendocrine Tumors.胃肠胰神经内分泌肿瘤。
Gastroenterol Clin North Am. 2022 Sep;51(3):625-647. doi: 10.1016/j.gtc.2022.06.002. Epub 2022 Aug 30.
4
[Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].[胃肠胰神经内分泌肿瘤:靶向诊断与治疗]
Chirurg. 2014 Aug;85(8):731-44. doi: 10.1007/s00104-013-2679-5.
5
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.胃肠胰神经内分泌肿瘤:当前的发展、挑战和临床观点。
Mil Med Res. 2024 Jun 4;11(1):35. doi: 10.1186/s40779-024-00535-6.
6
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.ENETS 高级别胃肠胰神经内分泌肿瘤和神经内分泌癌共识指南
Neuroendocrinology. 2016;103(2):186-94. doi: 10.1159/000443172. Epub 2016 Jan 5.
7
Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation.胃肠胰神经内分泌肿瘤的诊断和治疗:前瞻性采集、回顾性分析的临床多中心研究的最新数据。
Oncologist. 2011;16(5):602-13. doi: 10.1634/theoncologist.2011-0002. Epub 2011 Apr 5.
8
Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.胃泌素瘤神经内分泌肿瘤患者从首次肿瘤表现到确诊的时间:来自德国一家大型三级转诊中心的结果。
Medicine (Baltimore). 2021 Sep 17;100(37):e27276. doi: 10.1097/MD.0000000000027276.
9
Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.中国胃肠胰神经内分泌肿瘤的临床、病理及预后特征:一项回顾性研究
BMC Endocr Disord. 2014 Jul 8;14:54. doi: 10.1186/1472-6823-14-54.
10
Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.中国人群胃肠胰神经内分泌肿瘤的临床病理特征及预后:一项大型回顾性单中心研究
BMC Endocr Disord. 2017 Jul 13;17(1):39. doi: 10.1186/s12902-017-0190-6.

引用本文的文献

1
Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence.神经内分泌肿瘤的管理:卓越中心内外对指南的遵循情况
Endocr Connect. 2022 Jun 15;11(6):e220097. doi: 10.1530/EC-22-0097.
2
Evaluating cost-effectiveness in the management of neuroendocrine neoplasms.评估神经内分泌肿瘤管理的成本效益。
Rev Endocr Metab Disord. 2021 Sep;22(3):647-663. doi: 10.1007/s11154-020-09608-y. Epub 2020 Nov 6.
3
Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs).

本文引用的文献

1
A rationale for multidisciplinary care in treating neuroendocrine tumours.多学科治疗神经内分泌肿瘤的基本原理。
Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):306-13. doi: 10.1097/MED.0b013e32835570f1.
2
Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?镓-68生长抑素受体PET/CT:对于神经内分泌肿瘤患者,是时候用它取代(111)铟喷曲肽了吗?
Endocrine. 2012 Aug;42(1):3-4. doi: 10.1007/s12020-012-9681-4.
3
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
晚期胰腺神经内分泌肿瘤(PanNETs)患者的全身治疗选择
Cancers (Basel). 2020 Jul 21;12(7):1988. doi: 10.3390/cancers12071988.
4
Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.胰腺神经内分泌肿瘤:血清标志物、分期和治疗的综述。
World J Gastroenterol. 2020 May 21;26(19):2305-2322. doi: 10.3748/wjg.v26.i19.2305.
5
Results of a nationwide survey on multidisciplinary teams on thyroid cancer in Spain.一项关于西班牙甲状腺癌多学科团队的全国性调查结果。
Clin Transl Oncol. 2019 Oct;21(10):1319-1326. doi: 10.1007/s12094-019-02056-4. Epub 2019 Feb 5.
6
Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries.爱尔兰过去二十年支气管神经内分泌肿瘤患者的管理与随访:预期的不一致性与意外的发现
Int J Endocrinol. 2018 Aug 29;2018:1043287. doi: 10.1155/2018/1043287. eCollection 2018.
7
Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.肺高分化神经内分泌肿瘤(典型类癌和非典型类癌)的诊断与管理挑战:现状与未来考量
Oncologist. 2015 Oct;20(10):1123-31. doi: 10.1634/theoncologist.2015-0198. Epub 2015 Aug 25.
8
⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors.⁶⁸Ga-DOTA-TOC-PET/CT检测回肠神经内分泌肿瘤的心脏转移灶。
Endocrine. 2014 Sep;47(1):169-76. doi: 10.1007/s12020-013-0108-7. Epub 2013 Nov 23.
镓-68 生长抑素受体 PET 和 PET/CT 对胸和胃肠胰神经内分泌肿瘤患者的诊断性能:一项荟萃分析。
Endocrine. 2012 Aug;42(1):80-7. doi: 10.1007/s12020-012-9631-1. Epub 2012 Feb 20.
4
Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.胃肠胰神经内分泌肿瘤:诊断与治疗的新见解。
Endocrine. 2012 Feb;41(1):40-52. doi: 10.1007/s12020-011-9562-2. Epub 2011 Nov 29.
5
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).胃肠胰神经内分泌(包括类癌)肿瘤(NETs)管理指南。
Gut. 2012 Jan;61(1):6-32. doi: 10.1136/gutjnl-2011-300831. Epub 2011 Nov 3.
6
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.生物靶向治疗在胃肠胰神经内分泌肿瘤中的作用。
Endocrine. 2011 Oct;40(2):181-6. doi: 10.1007/s12020-011-9513-y. Epub 2011 Aug 26.
7
Multidisciplinary reference centers: the care of neuroendocrine tumors.多学科参考中心:神经内分泌肿瘤的治疗。
J Oncol Pract. 2010 Nov;6(6):e11-6. doi: 10.1200/JOP.2010.000098.
8
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).胃肠胰神经内分泌肿瘤(GEP-NETs)发病、治疗模式及预后因素分析:来自西班牙国家癌症登记处(RGETNE)的研究结果。
Ann Oncol. 2010 Sep;21(9):1794-1803. doi: 10.1093/annonc/mdq022. Epub 2010 Feb 5.
9
Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel.近期小肠类癌神经内分泌肿瘤患者的腹腔内纤维化。
QJM. 2010 Mar;103(3):177-85. doi: 10.1093/qjmed/hcp191. Epub 2010 Feb 1.
10
Proceedings of the 3rd ENETS Consensus Conference on Guidelines for the Standard of Care in Neuroendocrine Tumors, Palma de Mallorca, Spain, 2007.第三届神经内分泌肿瘤护理标准指南ENETS共识会议论文集,西班牙马略卡岛帕尔马,2007年
Neuroendocrinology. 2009;90(2):155-234. doi: 10.1159/000235970.